Sam Brusco, Associate Editor09.08.22
ReWalk Robotics has appointed Michael Lawless, CPA as its new chief financial officer (CFO). He will begin the roles on September 19.
Lawless has over 20 years’ experience leading finance and investor relations at life science and tech companies. He was most recently CFO consultant for Danforth Advisors. Before that he was CFO of Brooks Life Sciences. He also served as head of financial planning and analysis for Brooks Automation and PerkinElmer.
Lawless also led investor relations at four life sciences firms: Aegerion Pharmaceuticals, PerkinElmer, Momenta Pharmaceuticals, and CTI Molecular Imaging.
“Mike brings an extensive background in strategic finance and investor relations for leading life science businesses and will add significant value at ReWalk as we approach key milestones and anticipated upcoming growth,” Larry Jasinski, ReWalk’s CEO told the press. “He has a considerable track record in all aspects of the M&A process, which will be vital as we assess the acquisition of complementary businesses to supplement our organic growth. Additionally, his experience leading investor relations programs will greatly help our efforts to increase investors’ awareness of ReWalk’s opportunities, strengthen our investor base, and heighten our financial flexibility.”
“I am very pleased to join ReWalk at this important and positive inflection point in the growth of the business,” said Lawless. “The expected establishment by CMS of a benefit category for reimbursement of ambulation technology could enable ReWalk to provide access to our technology for many more spinal cord injury victims. Thanks to our strong balance sheet, we are well positioned to fund this organic growth and supplement it with accretive acquisitions.”
Lawless has over 20 years’ experience leading finance and investor relations at life science and tech companies. He was most recently CFO consultant for Danforth Advisors. Before that he was CFO of Brooks Life Sciences. He also served as head of financial planning and analysis for Brooks Automation and PerkinElmer.
Lawless also led investor relations at four life sciences firms: Aegerion Pharmaceuticals, PerkinElmer, Momenta Pharmaceuticals, and CTI Molecular Imaging.
“Mike brings an extensive background in strategic finance and investor relations for leading life science businesses and will add significant value at ReWalk as we approach key milestones and anticipated upcoming growth,” Larry Jasinski, ReWalk’s CEO told the press. “He has a considerable track record in all aspects of the M&A process, which will be vital as we assess the acquisition of complementary businesses to supplement our organic growth. Additionally, his experience leading investor relations programs will greatly help our efforts to increase investors’ awareness of ReWalk’s opportunities, strengthen our investor base, and heighten our financial flexibility.”
“I am very pleased to join ReWalk at this important and positive inflection point in the growth of the business,” said Lawless. “The expected establishment by CMS of a benefit category for reimbursement of ambulation technology could enable ReWalk to provide access to our technology for many more spinal cord injury victims. Thanks to our strong balance sheet, we are well positioned to fund this organic growth and supplement it with accretive acquisitions.”